Comprehensive coverage

cancer

The technology developed by Prof. Yuval Shaked's research group was registered as a patent and is now in the process of being commercialized
The cell's garbage disposal system changes in cancer and allows it to escape the immune system
Thanks to the nanoparticle system they developed - the cancer cell stops dividing and dies
This is the first time that researchers succeed in developing personalized tools for infectious diseases, which until now have only been developed for specific diseases such as cancer and Alzheimer's
Researchers at the Hebrew University and the Hadassah Medical Center have developed an ointment to treat the severe side effects of targeted cancer treatment and significantly improve the quality of life of patients.
The institute's scientists reveal how cancer leads to fatal emaciation and point the way to treatment
In the clinical trial, T Cell-CAR genetic engineering technology was used to program the patient's white blood cells to attack the cancerous blood tumors
The research was led by researchers from two faculties at the Technion and their colleague from the University of Tokyo
Pools of immune system cells taken from patients and mice with liver cancer and melanoma, partly composed of tired immune cells
Researchers from Tel Aviv University have shown that silent mutations, i.e. those that do not change the amino acid sequence of the proteins, are also not innocent
A marker developed in a new Israeli study by the University of Bar-in and applied by the start-up company Isotopia will not only determine if it is a malignant or benign tumor but also determine how aggressive it is, and all this will be done in one image and avoid a biopsy
A group of scientists at the Weizmann Institute of Science recently investigated what happens to cellular memory in cancer. Their findings illustrate how "memory loss" may affect the course of malignant diseases
Weizmann Institute of Science scientists, in collaboration with researchers from the National Cancer Institute and Ben-Gurion University of the Negev, recently found a genetic signature that differentiates between tumors that may respond to immunotherapy and tumors that are resistant to this treatment method. Besides better diagnostic tools for predicting the response of patients to immunotherapy
Science website logo
SEARCH
Skip to content